March 6, 2012--Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on bringing sustainable solutions to the plastics, chemicals and energy industries, today reported financial results for the three months and full year ended December 31, 2011.
FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL OVERVIEW
Total revenue in the fourth quarter of 2011 was $0.4 million, compared to $0.1 million for the comparable quarter in 2010. Research and development expenses were $6.1 million for the fourth quarter of 2011 compared to $5.8 million for the same period in 2010. Selling, general and administrative expenses were $4.0 million for the fourth quarter of 2011 as compared to $3.8 million for the comparable quarter in 2010. The Company reported a net loss of $9.6 million or $0.28 per share for the fourth quarter of 2011 compared to a net loss of $9.5 million or $0.35 per share for the fourth quarter of 2010.
The Company's net cash used for operating activities during the fourth quarter of 2011 was $8.6 million, which compares to net cash used of $8.1 million for the comparable quarter in 2010.Total revenue for the full year 2011 was $ 1.4 million, compared to $ 0.4 million, for the comparable quarter in 2010. The year-over-year increase was primarily due to an increase in 2011 in government research grant revenue, and an increase in license fee and royalty revenue as compared to 2010. For the full year 2011, research and development expenses were $24.4 million compared to $23.7 million for 2010. The increase was primarily due to an increase in contracted research related to Mirel product development and the Company’s biobased industrial chemicals program, employee compensation and related benefit expenses partially offset by a decrease in material production costs. For the full year 2011, selling, general and administrative expenses were $15.8 million as compared to $15.7 million in 2010.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV